Cargando…

Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus

Detalles Bibliográficos
Autores principales:	Bruce, Ian N, Golam, Sarowar, Steenkamp, Jason, Wang, Pearl, Worthington, Evelyn, Desta, Barnabas, Psachoulia, Konstantina, Erhardt, Wilma, Tummala, Raj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Becaris Publishing Ltd 2022
Materias:	Letter in Reply
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288956/ https://www.ncbi.nlm.nih.gov/pubmed/36515083 http://dx.doi.org/10.2217/cer-2022-0192

Ejemplares similares

Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
por: Ballew, Nick, et al.
Publicado: (2022)

Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
por: Neupane, Binod, et al.
Publicado: (2023)

Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment
por: Kirou, Kyriakos A., et al.
Publicado: (2022)

Anifrolumab for systemic lupus erythematosus
Publicado: (2022)

Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus
por: Chia, Yen Lin, et al.
Publicado: (2021)

Anifrolumab for Adolescent Discoid Lupus Erythematosus
por: Shaw, Katharina S., et al.
Publicado: (2023)

Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus
por: Almquist, Joachim, et al.
Publicado: (2022)

Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials
por: Bruce, Ian N, et al.
Publicado: (2023)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016)

Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus
por: Chia, Yen Lin, et al.
Publicado: (2022)

Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
por: Morand, Eric F, et al.
Publicado: (2023)

Reply
por: Villa, E, et al.
Publicado: (2001)

In reply:
por: Starčević Čizmarević, Nada, et al.
Publicado: (2021)

The Authors’ Reply
por: Mallik, Sarmila, et al.
Publicado: (2012)

The authors’ reply
por: El-Kannishy, Ghada M.
Publicado: (2018)

The authors’ reply
por: Kim, Hyo Shik, et al.
Publicado: (2017)

Authors’ reply
por: Myrtennäs, Kerstin, et al.
Publicado: (2017)

The author’s reply
por: Park, Chun Soo
Publicado: (2022)

The author’s reply
por: Park, Hyung Joo
Publicado: (2022)

Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus
por: Dimelow, Richard, et al.
Publicado: (2020)

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
por: Plüß, Marlene, et al.
Publicado: (2022)

Reply to Comment On: “Indirect Assessment of Skeletal Muscle Glycogen Content in Professional Soccer Players before and after a Match through a Non-Invasive Ultrasound Technology Nutrients 2020, 12(4), 971”
por: San-Millán, Iñigo, et al.
Publicado: (2020)

Reply to the Comment of G. Feulner
por: Weber, Werner
Publicado: (2011)

In Reply to: Fine Needle Aspiration
por: Ehsanbakhsh, Ali-Reza, et al.
Publicado: (2014)

Reply to the Comment by Littlechild and Isupov
por: Willetts, Andrew, et al.
Publicado: (2017)

Long‐Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open‐Label Extension Study
por: Chatham, W. Winn, et al.
Publicado: (2021)

Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab
por: Tang, Weifeng, et al.
Publicado: (2023)

Reply to “The Carotid Sinus as a Viscometer”
por: Lee, Ui Yun, et al.
Publicado: (2020)

Reply to ‘Management of noncompaction requires optimisation’
por: Gurunathan, Sothinathan, et al.
Publicado: (2019)

The Slopes Remain the Same: Reply to Wolfe (2016)
por: Kristjánsson, Árni
Publicado: (2016)

The Paradox of Ingestion of Dietary Cholesterol in “Vegans”—Reply
por: Clarys, Peter, et al.
Publicado: (2017)

Reply to “Dyslexia: Still Not a Neurodevelopmental Disorder”
por: Fraga González, Gorka, et al.
Publicado: (2019)

Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab
por: Guzman, Marla, et al.
Publicado: (2020)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

Reply to commentary on costs of diabetes and its complications in Poland
por: Leśniowska, Joanna
Publicado: (2014)

Correction to Figures: A Reply to Hwang and Peli (2014)
por: Gao, Zhongpai
Publicado: (2017)

Maximum Entropy Theory of Ecology: A Reply to Harte
por: Favretti, Marco
Publicado: (2018)

In reply to Unopposed Estrogen and Endometrial Cancer: Association or Causation?
por: Trkulja, Vladimir, et al.
Publicado: (2019)

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus
por: Merrill, Joan T, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_al6pbb4ojgq4g942074dl25m6p